Drug Name: Elahere
Active Ingredient: mirvetuximab soravtansine-gynx
Indications: To treat patients with recurrent ovarian cancer that is resistant to platinum therapy
Approval Date: 11/14/2022
Company: ImmunoGen, Inc
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf